Argent BioPharma Limited (FRA:H5O0)

Market Cap	2.15M -38.3%
Revenue (ttm)	97.60K -10.7%
Net Income	-4.67M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0105
Previous Close	0.0105
Day's Range	0.0105 - 0.0105
52-Week Range	0.0100 - 0.0550
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Argent BioPharma

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company’s principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer’s. It is also in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: H5O0

Financial Performance

In fiscal year 2026, Argent BioPharma's revenue was 161,187, a decrease of -10.73% compared to the previous year's 180,565. Losses were -7.71 million, -56.79% less than in 2025.

Financial numbers in AUD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 26, 2026

Data Sources Report a data error